← Back to Search

Monoclonal Antibodies

Romosozumab + Denosumab for Spinal Cord Injury

Phase 4

Recruiting

Led By Christopher P Cardozo, MD

Research Sponsored by James J. Peters Veterans Affairs Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Motor complete or incomplete SCI (every level of injury); International Standards for Neurological Classification of Spinal Cord Injury (ISNSCI) grade A-C (wheelchair dependent greater than 75% of the time)

Be older than 18 years old

Must not have

Bone cancer

Recent fracture or extensive bone trauma

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline to 24 months

Awards & highlights

Summary

This trial will study whether a combination of two drugs can help maintain bone mass in people with chronic SCI.

Who is the study for?

This trial is for males aged 18-65 and premenopausal females aged 18-55 with chronic spinal cord injury (SCI) of more than 3 years, who are mostly wheelchair-dependent. Participants must have low bone density at the knee and agree to use effective contraception. Exclusions include weakened immune systems, heart disease history, recent heavy anti-inflammatory or bone density medication use, jawbone issues, abnormal calcium levels, cancer within the last five years, certain endocrine disorders, major fractures or surgeries in the past year.

What is being tested?

The study tests if a year-long treatment with Romosozumab followed by Denosumab can maintain knee bone mass in people with long-term SCI. It compares these drugs against a placebo over a period of two years to see which is better at improving bone health.

What are the potential side effects?

Potential side effects may include joint pain, headaches, injection site reactions like redness or swelling for both medications. Romosozumab might also cause cardiovascular issues such as heart attacks or strokes; Denosumab could lead to skin problems like eczema or rashes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a spinal cord injury and use a wheelchair most of the time.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have bone cancer.

Select...

I have had a recent fracture or major injury to my bones.

Select...

I had low testes function before my spinal cord injury.

Select...

My immune system is currently weak or I have an infection.

Select...

I have jaw bone issues or had major dental work in the last 6 months.

Select...

I do not have severe chronic diseases like COPD, heart failure, or kidney failure.

Select...

I had a major leg bone break in the last year.

Select...

I have been diagnosed with cancer or had cancer in the last 5 years.

Select...

I have been on high dose steroids (more than 40 mg/day) for over a week.

Select...

I have a hormone-related condition like hyperthyroidism or Cushing's.

Select...

I have or had heart disease or a stroke.

Select...

I have been diagnosed with high calcium levels in my blood.

Select...

I am a woman who has gone through menopause.

Select...

I am taking medication for bone growth in the wrong places or for osteoporosis, excluding calcium and vitamin D.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Bone mineral density (BMD)

Side effects data

From 2022 Phase 4 trial • 37 Patients • NCT04026256

44%

joint pain

22%

nausea

22%

propagation of fracture at biopsy site

11%

dizziness

11%

rhinorrhea

100%

80%

60%

40%

20%

Study treatment Arm

Denosumab Only

Teriparatide Only

Denosumab and Teriparatide

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Romosozumab groupExperimental Treatment2 Interventions

Romosozumab (evenity) administered monthly from baseline to month 11 followed by denosumab (prolia) at month 12 and 18

Group II: Control groupPlacebo Group2 Interventions

Placebo administered monthly from baseline to month 11 followed by denosumab (prolia) at month 12 and 18

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Denosumab

FDA approved

0 / 15Eligibility criteria met

Find a Location

Who is running the clinical trial?

Kessler Institute for RehabilitationIndustry Sponsor

22 Previous Clinical Trials

1,126 Total Patients Enrolled

James J. Peters Veterans Affairs Medical CenterLead Sponsor

57 Previous Clinical Trials

2,861 Total Patients Enrolled

Christopher P Cardozo, MDPrincipal InvestigatorJames J Peters VA Medical Center

3 Previous Clinical Trials

25 Total Patients Enrolled

Media Library

Denosumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05180032 — Phase 4

Spinal Cord Injury Research Study Groups: Romosozumab group, Control group

Spinal Cord Injury Clinical Trial 2023: Denosumab Highlights & Side Effects. Trial Name: NCT05180032 — Phase 4

Denosumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05180032 — Phase 4

~4 spots leftby Mar 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.